{"SPADE_UN_13521": {"Clinical Information": [], "Patent Information": [], "Sequence Information": {"SPADE ID": "SPADE_UN_13521", "Peptide Name": "IPB01(SARS-CoV-S (1151-1185),SR9, SARS-CoV-2-S (1169-1203))", "Source": "Synthetic construct", "Family": "Belongs to the betacoronaviruses spike protein family.", "Gene": "S", "Sequence": "ISGINASVVNIQKEIDRLNEVAKNLNESLIDLQEL", "Sequence Length": 35, "UniProt Entry": ["http://www.uniprot.org/uniprot/P59594", "http://www.uniprot.org/uniprot/P0DTC2"], "Protein Existence": "Protein level", "Biological Activity": ["Antimicrobial", "Antiviral(SARS-CoV-2)"], "Target Organism": "[Ref.32376627]Virus:SARS-CoV-2:ihibition of cell-cell fusion in 293T/ACE2 cells(IC50=0.022±0.005 µM),inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC50=33.74±11.827 µM);SARS-CoV:inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC50>50 µM);Vesicular Stomatitis Virus (VSV):inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells(IC50>50 µM).[Ref.17942557]Virus:SARS-CoV:Inhibition of virus entry in VERO-E6 cells(EC50=0.005 µM).[Ref.18442051]Virus:SARS-CoV:inhibition of PsV entry in Vero-E6 cells(EC50=0.34 µM).", "Hemolytic Activity": "No hemolysis information or data found in the reference(s) presented in this entry", "Cytotoxicity": "No cytotoxicity information found in the reference(s) presented", "Binding Target": "liposomes", "Linear/Cyclic": "Linear", "N-terminal Modification": "Free", "C-terminal Modification": "Free", "Stereochemistry": "L", "Structure Description": "Not found", "Formula": "C168H287N47O58", "Mass": 3893.36, "PI": 4.36, "Net Charge": -3, "Hydrophobicity": -0.08, "Half Life": "Mammalian:20 hourYeast:30 minE.coli:>10 hour", "Mechanism of action": "The peptide was designed based on HR2 sequence lipopeptide fusion inhibitor,which showed highly potent activities in inhibiting SARS-CoV-2 S protein-mediated cell-cell fusion and pseudovirus transduction. It can  also inhibit the SARS-CoV pseudovirus efficiently.", "Literature": [{"Title": "Heptad repeat-derived peptides block protease-mediated direct entry from the cell surface of severe acute respiratory syndrome coronavirus but not entry via the endosomal pathway.", "Pubmed ID": "17942557", "Reference": "J Virol. 2008 Jan;82(1)588-92.", "Author": "Ujike M, Nishikawa H, Otaka A, Yamamoto N, Yamamoto N, Matsuoka M, Kodama E, Fujii N, Taguchi F.", "URL": "http://www.ncbi.nlm.nih.gov/pubmed/?term=17942557"}, {"Title": "Fusion core structure of the severe acute respiratory syndrome coronavirus (SARS-CoV) in search of potent SARS-CoV entry inhibitors.", "Pubmed ID": "18442051", "Reference": "J Cell Biochem. 2008 Aug 15;104(6)2335-47.", "Author": "Chu LH, Chan SH, Tsai SN, Wang Y, Cheng CH, Wong KB, Waye MM, Ngai SM.", "URL": "http://www.ncbi.nlm.nih.gov/pubmed/?term=18442051"}, {"Title": "Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity.", "Pubmed ID": "32376627", "Reference": "J Virol. 2020 Jul 1;94(14)e00635-20.", "Author": "Zhu Y, Yu D, Yan H, Chong H, He Y.", "URL": "http://www.ncbi.nlm.nih.gov/pubmed/?term=32376627"}], "Frequent Amino Acids": "ILN", "Absent Amino Acids": "CFHMOPTUWY", "Basic Residues": 3, "Acidic Residues": 6, "Hydrophobic Residues": 15, "Polar Residues": 18, "Positive Residues": 3, "Negative Residues": 6, "Similar Sequences": [{"SPADE_ID": "SPADE_UN_13518", "Similarity": 1.0, "Sequence": "DISGINASVVNIQKEIDRLNEVAKNLNESLIDLQEL"}, {"SPADE_ID": "SPADE_UN_13522", "Similarity": 1.0, "Sequence": "ISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELK"}, {"SPADE_ID": "SPADE_UN_13540", "Similarity": 1.0, "Sequence": "DISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGSGSGC"}]}}}